CD274 scFv-CD3ζ (1st) CAR Expression Plasmid

INTRODUCTION

Chimeric Antigen Receptors (CARs) are recombinant receptors that are composed of four regions: an antigen recognition domain (ectodomain), a hinge region, a transmembrane region, and an intracellular T cell signaling domain (endodomain). CAR-T cell therapy uses T cells engineered with CARs to target specific antigen(s) for cancer immunotherapy.

CD274 (also known as Programmed death-ligand 1, PD-L1) is a type I transmembrane protein. It is an immune inhibitory receptor ligand and is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The binding of PD-L1 to the inhibitory checkpoint molecule PD-1 inhibits T-cell activation and cytokine production. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. CD274 protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of cancers.

RGBiotech offers CD274 scFv-CD3ζ (1st) CAR Expression Plasmid to assist CAR-T research. This vector contains a first (1st) generation of CD274 CAR that consists of four major components: 1) anti-CD274 scFv as an extracellular antigen-binding domain, 2) a hinge region, 3) a transmembrane domain, and 4) CD3ζ (CDzeta, CD247) intracellular signaling domain.

HIGHLIGHTS

APPLICATIONS

Contact Us